Skip to content

Posts tagged ‘clinical trials’

To the Crick! Part 5: 100 years of tuberculosis research and 70,000 years of evolution

For our final post in the ‘To the Crick’ series, we hear from Luiz Pedro Carvalho. He’s moving from the site of what was the National Institute of Medical Research (NIMR) in Mill Hill to the new Francis Crick Institute building in King’s Cross. We find out about Luiz’s work, focused on tuberculosis (TB), and look back at over 100 years of MRC-funded TB research.

a side view of open-plan lab space inside the Crick

Open-plan lab spaces inside the Crick

“It’s a mixture of excitement and already missing the place,” says Luiz. Mill Hill was home to NIMR for most of its lifetime but activities there have nearly come to an end. The venerable institute is now part of the Francis Crick Institute.

Read more

Simple diagnostic saves lives

Professor of Obstetrics Andrew Shennan at King’s College London has developed a simple diagnostic device to measure blood pressure, pulse and detect shock in pregnant women. He’s now putting it to the test in a large trial across 10 centres in eight countries funded through the Joint Global Research Programme for Women’s and Children’s Health in collaboration with India’s Department of Biotechnology.

Pregnant woman stands in an alleyway with a bike

Photo credit: Meena Kadri under CC BY 2.0

It’s taken 10 years but we finally have it. It’s cheap, it’s easy to use and it could save the lives of thousands of women every year. Read more

Why MRC-industry asset sharing is a win-win for me

Just how useful is it to get access to a pharmaceutical company compound? Back in 2012 Dr Richard Mead of the University of Sheffield was one of 15 academic project leaders funded by the MRC to research an alternative use for a compound no longer being developed by AstraZeneca. As we launch the next round of the MRC-Industry Asset Sharing Initiative he tells us how the collaboration has brought together the best of both worlds.

Copyright: Richard Mead

Copyright: Richard Mead

I’m no stranger to the pharmaceutical industry. I spent three years in drug development at Celltech in the early 2000s. But even with my experience, it’s still amazing to be reminded of the resources that pharmaceutical companies have at their fingertips. It sounds obvious, but their access to unique compounds, and their ability to make them, is impressive. Read more